Not yet independently audited
This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.
COPD statistics quick reference¶
Last curated: 2026-10-27 (periodic sweep; new rows pending independent audit)
Prevalence and burden¶
| Figure | Source/year | Population | Method |
|---|---|---|---|
| 391.9 million people; 10.3% prevalence | Adeloye 2022, PMID 35279265 | Adults 30–79, global, 2019 | Systematic review and modeling; fixed FEV1/FVC |
| Global/regional prevalence estimates | Adeloye 2015, PMID 26755942 | Population spirometry studies | Systematic review/meta-analysis |
| Burden in 195 countries, 1990–2017 | GBD CRD 2020, PMID 32526187 | Global | GBD comparative modeling |
| Burden and attributable risks in 204 countries, 1990–2019 | Safiri 2022, PMID 35896191 | Global | GBD 2019 modeling |
| COPD burden projection through 2050 | Boers 2023, PMID 38060225 | Global | Demographic/risk projection |
| USA 2023: 54.50 million (95% UI 48.86–61.60) living with chronic respiratory disease (all four GBD causes); projected 19.61 million (16.70–22.26) with COPD by 2050; highest age-standardised COPD mortality in Appalachian states | GBD 2023 US Chronic Respiratory Disease Collaborators 2026, PMID 42753772 | USA, state level, 1990–2023 with forecast | GBD 2023 modelling; ecological links to cigarette tax/vaccination are associations, not effects |
| Japan: COPD prevalence 8.6% of adults >40, with <10% formally diagnosed | Sugiura 2026 (JRS guideline summary), PMID 42447589 | Japan | Figure quoted by the guideline; underlying survey not identified in the abstract |
| GOLD stage II+ prevalence 10.1% overall; 11.8% men; 8.5% women | Buist 2007, PMID 17765523 | 9,425 adults, 12 BOLD sites | Standardized post-bronchodilator population survey |
| Stage II+ COPD OR 1.94 (95% CI 1.80–2.10) per decade of age | Buist 2007, PMID 17765523 | BOLD sites | Pooled logistic models |
| COPD prevalence 7.8% (95% CI 5.9–9.7) in Mexico City to 19.7% (17.2–22.2) in Montevideo | Menezes 2005, PMID 16310554 | Adults ≥40 in five Latin-American cities | PLATINO probability samples; post-BD fixed ratio |
| São Paulo COPD prevalence 15.8% (95% CI 13.5–18.1) | Menezes 2005, PMID 16158163 | Adults >40, metropolitan São Paulo | PLATINO probability sample; post-BD fixed ratio |
| Never-smoker COPD 10.5% (95% CI 9.1–12.1) by fixed ratio versus 4.6% by LLN | Ivey 2024, PMID 38249822 | 1,656 never-smokers aged ≥40, BOLD Australia | Cross-sectional post-BD spirometry |
| COPD prevalence 8.2%; men 12.4%, women 5.1%; 35.3% asymptomatic; 6.5% previously tested by spirometry | Zhong 2007, PMID 17575095 | 20,245 adults aged ≥40 across seven Chinese regions | Population survey; post-BD fixed ratio; 79.0% response |
| Per later birth year: FVC +21.4 mL, FEV1 +24.6 mL, FEV1/FVC +0.25% | Ma 2026, PMID 42760129 | 28,569 BOLD adults born 1902–1976, 41 sites in 34 countries | Fully adjusted birth-cohort models; consistent in HICs and LMICs; abstract-level |
Official-portal snapshots checked 2026-10-27¶
| Figure | Source / publication date | Population and method | Interpretation |
|---|---|---|---|
| COPD deaths in 2023: 3.6 million; third leading cause | WHO — “The top 10 causes of death,” https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death, published 2026-10-02, accessed 2026-10-27 | Global; WHO cause-of-death estimates | Conflicts with the COPD fact sheet below; retain source version/date rather than average |
| COPD deaths in 2023: 3.4 million; third leading cause | WHO — “Chronic obstructive pulmonary disease (COPD),” https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd), published 2026-06-10, accessed 2026-10-27 | Global; WHO fact-sheet summary | Same stated year, different total; discrepancy unresolved in this sweep |
| 4.4% of adults ever diagnosed with COPD, emphysema or chronic bronchitis (2025) | CDC/NCHS — “Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema,” https://www.cdc.gov/nchs/fastats/copd.htm, accessed 2026-10-27 | USA; National Health Interview Survey, reported clinician diagnosis | Diagnosed prevalence, not spirometry-defined prevalence; portal publication/update date not established |
| Chronic lower respiratory disease deaths: 145,643; 42.8 per 100,000; rank 5 (2024) | CDC/NCHS — FastStats page above, accessed 2026-10-27 | USA; NVSS mortality via CDC WONDER; includes asthma | Broader cause group than COPD; do not label this a COPD-only death count or age-adjusted rate |
Diagnostic and natural-history figures¶
| Figure | Source/year | Population | Method |
|---|---|---|---|
| Fixed post-BD FEV1/FVC <0.70 is the operational GOLD obstruction criterion | Vestbo 2013, PMID 22878278 | Clinical COPD evaluation | Strategy synthesis |
| Prior exacerbation predicts future susceptibility | Hurst 2010, PMID 20843247 | ECLIPSE longitudinal cohort | Prospective event follow-up |
| US PRISm and COPD have separable prevalence/mortality risk | Cadham 2024, PMID 38750492 | NHANES 2007–2012 | Population cohort linkage |
| COPD after 22 years: 26% with FEV1 <80% predicted before 40 versus 7% with preserved early FEV1 | Lange 2015, PMID 26154786 | Three longitudinal cohorts | Trajectory analysis |
| Approximate mean FEV1 decline 53±21 mL/year in normal-attainment/rapid-decline COPD versus 27±18 mL/year in low-attainment COPD | Lange 2015, PMID 26154786 | Three longitudinal cohorts | Retrospective trajectory grouping |
| Normal-attainment/rapid-decline versus low-attainment COPD: all-cause mortality HR 1.93 (95% CI 1.14–3.26) | Marott 2020, PMID 32289231 | Copenhagen City Heart Study | Longitudinal cohort |
| Terminal bronchioles reduced 72–89%; total cross-sectional area reduced 81–99.7% in GOLD 4 explants | McDonough 2011, PMID 22029978 | COPD transplant explants versus donor controls | Micro-CT and CT pathology |
| Persistent systemic inflammation: mortality 13% versus 2%; exacerbations 1.5 versus 0.9/year | Agustí 2012, PMID 22624038 | 1,755 ECLIPSE COPD participants | Three-year biomarker cohort |
| CT mucus plugs: mortality 34.0%, 46.7%, 54.1% for 0, 1–2, ≥3 plugged segments | Diaz 2023, PMID 37210745 | 4,363 COPDGene participants; median 9.5 years | Adjusted observational cohort |
| CT mucus plugs pooled: mortality HR 1.14 (1.03–1.26) low-grade, 1.48 (0.86–2.54) high-grade; severe exacerbation HR 1.11 (1.00–1.22) and 1.41 (1.04–1.91) | Pu 2026, PMID 42097456 | 15,702 patients in 7 observational studies | Random-effects meta-analysis |
| Fixed-ratio outcome optimum 0.71; C-statistic difference versus 0.70, 0.001 (95% CI −0.002 to 0.004) | Bhatt 2019, PMID 31237643 | 24,207 adults; 3,925 COPD hospitalizations/deaths over median 15 years | Four pooled US cohorts; prognostic discrimination, not diagnostic adjudication |
| Case-finding plus specialist/educator care: respiratory-use IRR 0.48 (95% CI 0.36–0.63); FEV1 difference +94 mL (50–138) | Aaron 2024, PMID 38767248 | 508 symptomatic adults with newly diagnosed asthma or COPD | One-year randomized care-pathway trial |
| Each SD greater CT Pi10: incident COPD OR 2.22 (95% CI 1.43–3.45); respiratory hospitalization/death risk +57% | Oelsner 2018, PMID 29529382 | 1,830 MESA adults without baseline chronic lower-respiratory disease | Adjusted population cohort; 78,147 person-years |
Treatment effects and boundaries¶
| Finding | Source/year | Population | Method |
|---|---|---|---|
| Smoking intervention reduced 14.5-year all-cause mortality | Anthonisen 2005, PMID 15710956 | Smokers with mild/moderate obstruction | Randomized intervention follow-up |
| LABA/LAMA reduced exacerbations versus LABA/ICS in FLAME | Wedzicha 2016, PMID 27181606 | Exacerbation-risk COPD | 52-week RCT |
| Triple therapy reduced moderate/severe exacerbations but increased pneumonia versus LABA/LAMA in IMPACT | Lipson 2018, PMID 29668352 | Symptomatic exacerbation-prone COPD | 52-week RCT |
| ETHOS higher-dose triple reduced exacerbations versus dual comparators | Rabe 2020, PMID 32579807 | Moderate-to-very severe COPD with event history | 52-week RCT |
| Azithromycin reduced exacerbations over one year with hearing/resistance concerns | Albert 2011, PMID 21864166 | Selected high-risk COPD | RCT |
| PR improves exercise capacity and health-related quality of life | McCarthy 2015, PMID 25705944 | Stable COPD trials | Cochrane review |
| Continuous oxygen improved survival versus nocturnal oxygen in severe hypoxemia | NOTT 1980, PMID 6776858 | Severe chronic hypoxemic COPD | RCT |
| Oxygen did not improve death/first hospitalization in moderate resting/exercise desaturation | Albert 2016, PMID 27783918 | Stable moderate desaturation | RCT |
| Home NIV plus oxygen prolonged time to readmission/death | Murphy 2017, PMID 28528348 | Persistent hypercapnia after life-threatening event | RCT |
| Zephyr valves improved lung function, exercise and health status with pneumothorax risk | Criner 2018, PMID 29787288 | Heterogeneous emphysema, no collateral ventilation | RCT |
| Dupilumab reduced annualized moderate/severe exacerbations in eosinophilic chronic-bronchitis COPD | Bhatt 2023, PMID 37272521 | Eosinophils ≥300/µL despite triple therapy | Phase 3 RCT |
| Dupilumab result replicated | Bhatt 2024, PMID 38767614 | Similar selected population | Phase 3 RCT |
| Tiotropium maintained 87–103 mL pre-BD FEV1 advantage but did not alter post-day-30 decline | Tashkin 2008, PMID 18836213 | 5,993 participants over four years | UPLIFT RCT |
| Tiotropium versus salmeterol: first exacerbation HR 0.83 (95% CI 0.77–0.90); severe-event rate ratio 0.73 (0.66–0.82) | Vogelmeier 2011, PMID 21428765 | 7,376 exacerbation-risk participants | POET-COPD RCT |
| ICS withdrawal: first moderate/severe exacerbation HR 1.06 (95% CI 0.94–1.19); trough FEV1 −43 mL at week 52 | Magnussen 2014, PMID 25196117 | 2,485 severe COPD participants after triple run-in | WISDOM non-inferiority RCT |
| Five versus 14 days prednisone: re-exacerbation difference −1.2 points (95% CI −12.2 to 9.8); cumulative dose 379 versus 793 mg | Leuppi 2013, PMID 23695200 | 314 acute exacerbations, 92% hospitalized | REDUCE non-inferiority RCT |
| Eosinophil-guided acute steroids: median 2 versus 5 days; 30-day failure 26% versus 26% | Sivapalan 2019, PMID 31122894 | 318 hospitalized exacerbations | CORTICO-COP non-inferiority RCT |
| Home versus centre PR at completion: 6MWD +18.6 m (95% CI −3.3 to 40.7); gains not maintained at 12 months | Holland 2017, PMID 27672116 | 166 stable COPD participants | Equivalence RCT |
| Supported self-management reduced COPD admissions 39.8% and emergency visits 41.0% | Bourbeau 2003, PMID 12622605 | Advanced COPD with prior admission | Multicenter RCT |
| Severe-hypoxemia oxygen: five-year deaths 19/42 versus 30/45 | MRC Working Party 1981, PMID 6110912 | Severe hypoxemia/cor pulmonale | Controlled randomized trial |
| CO2-targeted NIV: one-year mortality 12% versus 33%; HR 0.24 (95% CI 0.11–0.49) | Köhnlein 2014, PMID 25066329 | Stable GOLD 4 COPD, PaCO2 ≥51.9 mm Hg | Multicenter RCT |
| NETT overall mortality RR 1.01; upper-lobe/low-exercise RR 0.47; non-upper-lobe/high-exercise RR 2.06 | Fishman 2003, PMID 12759479 | 1,218 severe emphysema participants after PR | LVRS RCT with subgroup interaction |
| TRANSFORM ≥12% FEV1 response 55.4% versus 6.5%; 6MWD difference +78.7 m | Kemp 2017, PMID 28885054 | Heterogeneous emphysema without collateral ventilation | Valve RCT |
| Ensifentrine FEV1 AUC +87 mL (95% CI 55–119) and +94 mL (65–124); event rate ratios 0.64 and 0.57 | Anzueto 2023, PMID 37364283 | 760 and 789 moderate/severe COPD participants | Replicate ENHANCE phase 3 RCTs |
| Mepolizumab 0.80 versus 1.01 moderate/severe events/year; rate ratio 0.79 (95% CI 0.66–0.94) | Sciurba 2025, PMID 40305712 | Eosinophils ≥300/µL despite triple therapy | MATINEE phase 3 RCT |
| SUMMIT mortality HR 0.88 (95% CI 0.74–1.04); cardiovascular composite HR 0.93 (0.75–1.14) | Vestbo 2016, PMID 27203508 | 16,485 moderate-COPD participants with cardiovascular risk | Four-arm RCT |
| Nocturnal oxygen: death/progression to LTOT 39.0% versus 42.0%; difference −3.0 points (95% CI −15.1 to 9.1) | Lacasse 2020, PMID 32937046 | 243 with isolated nocturnal desaturation | Under-recruited sham-controlled RCT |
| Post-acute NIV: readmission/death 65% versus 64% at one year despite PaCO2 improvement | Struik 2014, PMID 24781217 | 201 with hypercapnia >48 h after ventilatory support | RCT |
| Procalcitonin protocols: antibiotic prescribing RR 0.56 (95% CI 0.43–0.73); mortality RR 0.99 (0.58–1.69) | Mathioudakis 2017, PMID 28143877 | 1,062 exacerbations in eight trials | Meta-analysis; low/moderate certainty |
| Telerehabilitation versus center PR: 6MWD MD 0.06 m (95% CI −10.82 to 10.94); completion 93% versus 70% | Cox 2021, PMID 33511633 | 1,904 participants in 15 studies; 99% COPD | Cochrane synthesis |
| ICS-containing versus non-ICS inhaled therapy mortality OR 0.90 (95% CI 0.84–0.97); triple therapy OR 0.73 (0.59–0.91) | Chen 2023, PMID 35921883 | 103,034 participants in 60 RCTs | Meta-analysis; subgroup and comparator-selection caveats |
| Early supervised post-exacerbation PR mortality RR 0.58 (95% CI 0.35–0.98); readmission RR 0.47 (0.29–0.75) | Ryrsø 2018, PMID 30219047 | 801 participants in 13 RCTs | Meta-analysis; mortality based on four trials/319 participants |
| Ambulatory oxygen: 56% achieved clinically important short-term CRQ response, but 41% of acute/short-term responders declined continuation | Eaton 2002, PMID 12212960 | 41 non-chronically-hypoxemic participants with exertional SpO2 ≤88% | 12-week double-blind crossover RCT |
| RENEW coils: 6MWD difference +14.6 m; ≥25-m responders 40.0% versus 26.9%; SGRQ difference −8.9 points | Sciurba 2016, PMID 27179849 | 315 severe-emphysema participants | Randomized trial; benefit below mean 6MWD MCID with procedural harms |
| Metoprolol: first-exacerbation HR 1.05 (95% CI 0.84–1.32); hospitalized exacerbation HR 1.91 (1.29–2.83) | Dransfield 2019, PMID 31633896 | 532 exacerbation-prone patients without cardiac beta-blocker indication | Early-stopped placebo-controlled RCT |
| Metoprolol without CVD: composite exacerbation/CV event/death 27% versus 30%, HR 0.87 (0.73–1.05); SAEs 9.4% versus 7.8% | Sundh 2026, PMID 42701865 | 1,695 COPD patients without cardiovascular disease, Sweden | Pragmatic open-label phase 4 RCT, 1 year |
| Itepekimab exacerbation RR 0.81 (95% CI 0.61–1.07) overall; former-smoker subgroup RR 0.58 (0.39–0.85) | Rabe 2021, PMID 34302758 | 343 moderate-to-severe COPD participants | Phase 2a RCT; overall primary endpoint not met |
| Astegolimab exacerbation rate ratio 0.78 (95% CI 0.53–1.14; p=0.19) | Yousuf 2022, PMID 35339234 | Moderate-to-very-severe COPD | Phase 2a RCT; primary endpoint not met |
| Tozorakimab moderate/severe exacerbation RR 0.70 (0.58–0.85) OBERON and 0.71 (0.59–0.84) TITANIA, overall population | Sciurba 2026, PMID 42708515 | 877 and 873 exacerbation-prone current/former smokers, no eosinophil criterion | Replicate phase 3 RCTs, 52 weeks |
| Astegolimab Q2W RR 0.85 (0.72–1.00) ALIENTO and 0.85 (0.72–1.01) ARNASA; pooled 0.85 (0.76–0.96) | Papi 2026, PMID 42150581; Wedzicha 2026, PMID 42148875 | 1,301 + 1,375 frequent exacerbators | Phase 2b + phase 3 RCTs and prespecified pool; ARNASA lead dose not significant |
| Dupilumab ED visit/hospital admission RR 0.62 (0.43–0.90) | Bhatt 2026, PMID 42153327 | 1,874 BOREAS + NOTUS participants | Pooled phase 3 analysis |
| AATD IV augmentation: exacerbation MD +0.29/year (0.04–0.54); mortality OR 0.30 (0.03–2.98) | Glaister 2026, PMID 42626936 | 526 randomized in 6 RCTs (4 IV, 2 inhaled) | Cochrane review 2026; low-certainty evidence |
| Valves: peri-procedural (≤90 d) mortality Peto OR 3.70 (1.07–12.84); >90 d 0.50 (0.12–2.09) | Mari 2026, PMID 42500855 | 819 patients in 6 RCTs | Meta-analysis |
| Targeted lung denervation: first moderate/severe exacerbation HR 1.268 (0.988–1.628) | Shah 2025, PMID 40920914 | 388 GOLD E patients, AIRFLOW-3 | Sham-controlled RCT; primary endpoint not met |
Registry-only phase 3 snapshot — 2026-10-27¶
| Finding | Source / posting date | Population and method | Boundary |
|---|---|---|---|
| Itepekimab Q2W exacerbation RR 0.729 (95% CI 0.598–0.890) in AERIFY-1; 0.984 (0.803–1.206) in AERIFY-2 | ClinicalTrials.gov primary-outcome tables: NCT04701983 (results first posted 2026-10-15), NCT04751487 (2026-10-09); v2 API accessed 2026-10-27 | Former-smoker primary populations; randomized comparisons with placebo; negative-binomial models | Registry reports, not a peer-reviewed results paper; benefit was not replicated in AERIFY-2. These are primary-outcome cohorts, not total enrollment, and not a smoking-status interaction test |
Multidimensional outcomes and systemic burden¶
| Figure | Source/year | Population | Method |
|---|---|---|---|
| BODE all-cause mortality HR 1.34 (95% CI 1.26–1.42) per point; C statistic 0.74 versus 0.65 for FEV1 | Celli 2004, PMID 14999112 | 625-person prospective validation cohort | Multidimensional prognostic index |
| COTE ≥4 associated with approximately 2.2-fold mortality risk across BODE quartiles | Divo 2012, PMID 22561964 | 1,664 COPD participants; 79 comorbidities recorded | Prospective multicenter cohort |
| Cardiovascular event HR 3.8 (95% CI 2.7–5.5) in 30 days after exacerbation; HR 9.9 (6.6–14.9) after hospitalized event | Kunisaki 2018, PMID 29442524 | 16,485 SUMMIT participants with CVD/risk | Post hoc adjudicated cohort analysis |
| Frailty prevalence 32.07% (95% CI 26.64–37.49); mortality HR 1.68 (1.37–2.05); 6MWD −90.23 m | Wang 2023, PMID 37173728 | 20 studies, 11,620 participants | Systematic review/meta-analysis |
| Osteoporosis prevalence 38% (95% CI 34–43); COPD OR 2.83; low BMI OR 4.26; sarcopenia OR 3.65 | Chen 2019, PMID 31352034 | 58 studies | Systematic review/meta-analysis |
| Cardiovascular events after severe exacerbation, days 1–14: HR 14.5 (95% CI 12.2–17.3) | Graul 2024, PMID 38127850 | 213,466 people with COPD in England | Linked population cohort |
| Lung-cancer risk after COPD: RR 2.22 (95% CI 1.66–2.97); never-smoker restricted combined estimate 1.22 (0.97–1.53) | Brenner 2011, PMID 21483846 | 16 COPD studies within a systematic review | Random-effects meta-analysis |
| Fibrinogen ≥350 mg/dL: hospitalized-exacerbation HR 1.64 (95% CI 1.39–1.93), mortality HR 1.94 (1.62–2.31) | Mannino 2015, PMID 25685850 | 6,376 pooled COPD participants | Prognostic/enrichment analysis |
| Proteobacteria-dominant sputum microbiome mortality HR 2.58 (95% CI 1.43–4.66) versus Firmicutes dominance | Dicker 2021, PMID 32353489 | 253 stable COPD participants; median four-year follow-up | 16S cohort; association, not causal effect |
| Doubling fibrinogen mortality HR 2.2 (95% CI 1.3–3.7); adding it to MR-proADM did not improve AUC (0.83 vs 0.82; p=0.34) | Zuur-Telgen 2021, PMID 34886719 | 640 stable and 262 hospitalized COPD participants | Three-year cohort; incremental-prediction analysis |
Safety signals¶
| Signal | Source/year | Population | Method |
|---|---|---|---|
| ICS increases pneumonia risk; magnitude varies by molecule/dose | Zhang 2020, PMID 32643439 | COPD RCTs | Meta-analysis |
| Pneumothorax is a major early endobronchial-valve hazard | Criner 2018, PMID 29787288 | LIBERATE | RCT safety outcome |
| Low-dose extended-release morphine did not show uniform chronic-breathlessness benefit | Ekström 2022, PMID 36413230 | COPD with chronic breathlessness | BEAMS RCT |
| TRANSFORM pneumothorax 19/65 treated participants (29.2%) | Kemp 2017, PMID 28885054 | Selected heterogeneous emphysema | Valve RCT |
| WISDOM ICS withdrawal reduced trough FEV1 by 43 mL at week 52 despite exacerbation non-inferiority | Magnussen 2014, PMID 25196117 | Severe COPD after triple run-in | RCT harm/tradeoff |
| Pulmonary embolism prevalence 12% (95% CI 9–16%); mortality OR 5.30 (2.48–11.30) | Sato 2021, PMID 34879475 | 4,093 acute exacerbations in 16 studies | Protocolized-study meta-analysis; I2 94.8% |
| Pulmonary embolism 11% (95% CI 6–17%) and DVT 9% (6–12%) during acute exacerbation | Han 2022, PMID 35355978 | 5,854 participants in 20 studies | Systematic review/meta-analysis; ascertainment timing varied |
| Troponin elevation during hospitalized exacerbation: all-cause mortality OR 1.69 (95% CI 1.25–2.29) | Pavasini 2015, PMID 25965630 | Eight-study meta-analysis | Adjusted prognostic associations; myocardial-injury mechanisms heterogeneous |
Known conflicts and caveats¶
- Prevalence estimates differ by fixed ratio versus LLN, pre- versus post-bronchodilator testing, age range and survey access; do not average them.
- GBD results are modeled estimates, not direct global spirometry counts.
- Trial populations are enriched and underrepresent never-smokers, lower-resource settings, frailty and multimorbidity.
- Secondary mortality analyses in triple-therapy trials require caution because of prior ICS withdrawal and multiple testing.
- Short-term physiological improvement does not imply survival or admission benefit.
- Registry status and burden projections are dated snapshots.
- Subgroup effects such as NETT's mortality interaction are credible only when the interaction and biological selection are considered; they must not be generalized to all severe emphysema.
- Non-inferiority results depend on the prespecified margin: “non-inferior” is not “identical.”
- Biomarker-enriched trials estimate effects in the enriched population; they do not validate the cutoff as a universal biological boundary.